Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
Iteos Therapeutics, Inc. (ITOS) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies designed to counteract cancer's immunosuppressive mechanisms. This page provides investors and researchers with timely, verified updates on the company's clinical developments, strategic partnerships, and scientific milestones.
Discover comprehensive coverage of clinical trial progress, regulatory filings, and research innovations across Iteos' pipeline programs. Key focus areas include updates on their adenosine A2A receptor antagonist, TIGIT-targeted antibodies, and other therapies addressing tumor microenvironment challenges.
All content is curated to provide stakeholders with actionable insights while maintaining strict compliance with financial disclosure standards. Users can expect neutral reporting on material events without speculative analysis, ensuring reliable information for informed decision-making.
Bookmark this page for streamlined access to Iteos' latest announcements, including earnings reports, patent developments, and collaboration news. Regularly updated to reflect the company's progress in advancing next-generation cancer immunotherapies.
iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics, has announced its participation in two upcoming investor conferences in September 2024. The company will be present at the Wells Fargo Healthcare Conference on September 4 in Boston, and the Cantor Fitzgerald Global Healthcare Conference on September 18 in New York.
At both events, iTeos management will engage in fireside chats and one-on-one investor meetings. The Wells Fargo conference presentation is scheduled for 4:30 PM ET, while the Cantor Fitzgerald conference presentation will take place at 10:20 AM ET. Interested parties can access live webcasts of the presentations through the Investors section of iTeos' website, with archived replays available for approximately 30 days post-event.
iTeos Therapeutics (Nasdaq: ITOS) announced that interim data from the Phase 2 GALAXIES Lung-201 study will be presented at the European Society for Medical Oncology (ESMO) Congress 2024. The study, sponsored by iTeos' partner GSK, assesses the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer. The presentation, titled 'Interim Analysis of GALAXIES Lung-201,' is scheduled for September 14, 2024, at 8:30 am CEST as a late-breaking oral presentation. This Phase 2 randomized, open-label platform study focuses on patients with PD-L1 high (TPS ≥50%) NSCLC. The abstract will be published on the ESMO website at 00:05 am CEST on the day of the presentation.
iTeos Therapeutics (Nasdaq: ITOS) reported Q2 2024 financial results and provided business updates. Key highlights include:
- Multiple clinical milestones expected in H2 2024, including two Phase 2 trials of belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC
- Pro forma cash and investments of $714.4 million as of June 30, 2024, expected to provide runway through 2027
- Q2 2024 R&D expenses increased to $36.7 million from $29.2 million in Q2 2023
- Q2 2024 net loss of $7.1 million ($0.18 per share) compared to $34.3 million ($0.96 per share) in Q2 2023
The company is advancing multiple clinical programs, including belrestotug for NSCLC and HNSCC, and adenosine pathway inhibitors inupadenant and EOS-984.
iTeos Therapeutics (Nasdaq: ITOS) has appointed David Feltquate, M.D., Ph.D., as Chief Medical Officer. Dr. Feltquate will oversee the company's clinical development and regulatory strategies. He brings nearly 20 years of experience in immuno-oncology clinical development, translational medicine, and diagnostic assay advancement.
Prior to joining iTeos, Dr. Feltquate served as Chief Medical Officer at Palleon Pharmaceuticals and held leadership positions at Novartis and Bristol Myers Squibb. Notably, he was responsible for the clinical development of the first PD-1 inhibitor at Bristol Myers Squibb. Dr. Feltquate's appointment comes at a pivotal moment for iTeos as it aims to become a leading oncology company and advance its pipeline, including its TIGIT franchise.
iTeos Therapeutics announced the dosing of the first patient in its GALAXIES Lung-301 Phase 3 trial, testing the combination of belrestotug and dostarlimab against placebo and pembrolizumab in patients with advanced PD-L1 high NSCLC. The milestone has triggered a $35 million payment from GSK, iTeos' partner. This trial is the first to evaluate the TIGIT:PD-1 doublet therapy, informed by promising interim Phase 2 results. iTeos and GSK's collaboration, established in June 2021, included a $625 million upfront payment with potential milestone payments up to $1.45 billion and a profit-sharing agreement in the US.
iTeos Therapeutics and GSK have commenced the Phase 3 GALAXIES Lung-301 study to evaluate the combination of belrestotug and dostarlimab in untreated, unresectable, locally advanced, or metastatic PD-L1 selected non-small cell lung cancer (NSCLC). This landmark study will enroll approximately 1,000 patients globally, comparing the doublet therapy to a placebo plus pembrolizumab. The study's primary endpoints include progression-free survival and overall survival. Encouraging interim results from the Phase 2 GALAXIES Lung-201 study showed significant tumor reduction and a favorable safety profile with belrestotug and dostarlimab, prompting the initiation of the Phase 3 trial.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) reported positive results for the belrestotug + dostarlimab combination in lung cancer, completed successful enrollment in head and neck cancer trials, and raised $120 million in a direct offering. The company's cash balance of $715 million as of May 10, 2024, is expected to fund operations through 2027.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced a $120 million Registered Direct Offering led by existing investors RA Capital Management and Boxer Capital. The purchase price of $17.50 per share represents a premium of approximately 44% to the last close. This offering strengthens the company's balance sheet, increasing the pro forma cash position to $715 million, extending anticipated runway through 2027.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
